Követés
Adam Brufsky
Adam Brufsky
Professor of Medicine, University of Pittsburgh
E-mail megerősítve itt: upmc.edu
Cím
Hivatkozott rá
Hivatkozott rá
Év
Comprehensive molecular portraits of human breast tumours
Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park ...
Nature 490 (7418), 61-70, 2012
99062012
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 379 (2), 111-121, 2018
15872018
Prospective validation of a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
13282015
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
11492011
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
E Giovannucci, MJ Stampfer, K Krithivas, M Brown, A Brufsky, J Talcott, ...
Proceedings of the National Academy of Sciences 94 (7), 3320-3323, 1997
10631997
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
7192018
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
6902009
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with …
S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ...
Journal of clinical oncology 26 (10), 1664-1670, 2008
6222008
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
HD Bear, G Tang, P Rastogi, CE Geyer Jr, A Robidoux, JN Atkins, ...
New England Journal of Medicine 366 (4), 310-320, 2012
5442012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus …
EH Romond, JH Jeong, P Rastogi, SM Swain, CE Geyer Jr, MS Ewer, ...
Journal of Clinical Oncology 30 (31), 3792, 2012
5122012
RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line …
AM Brufsky, S Hurvitz, E Perez, R Swamy, V Valero, V O'Neill, HS Rugo
Journal of clinical oncology 29 (32), 4286-4293, 2011
4522011
Cognitive impairment associated with adjuvant therapy in breast cancer
CM Bender, SM Sereika, SL Berga, VG Vogel, AM Brufsky, KK Paraska, ...
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2006
4252006
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
A Robidoux, G Tang, P Rastogi, CE Geyer Jr, CA Azar, JN Atkins, ...
The lancet oncology 14 (12), 1183-1192, 2013
3932013
Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer
A Brufsky, WG Harker, JT Beck, R Carroll, E Tan-Chiu, C Seidler, ...
Journal of Clinical Oncology 25 (7), 829-836, 2007
3772007
Sacituzumab govitecan in metastatic triple-negative breast cancer
A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ...
New England Journal of Medicine 384 (16), 1529-1541, 2021
3752021
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER
AM Brufsky, M Mayer, HS Rugo, PA Kaufman, E Tan-Chiu, D Tripathy, ...
Clinical Cancer Research 17 (14), 4834-4843, 2011
3612011
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ...
New England journal of medicine 380 (25), 2395-2405, 2019
3352019
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
The Lancet Oncology 21 (4), 519-530, 2020
3292020
Practical guidance for the management of aromatase inhibitor-associated bone loss
P Hadji, JJ Body, MS Aapro, A Brufsky, RE Coleman, T Guise, A Lipton, ...
Annals of Oncology 19 (8), 1407-1416, 2008
2882008
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial
C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ...
Journal of Clinical Oncology 38 (27), 3138, 2020
2872020
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20